ES2391914T3 - Formulación farmacéutica tópica - Google Patents
Formulación farmacéutica tópica Download PDFInfo
- Publication number
- ES2391914T3 ES2391914T3 ES08709428T ES08709428T ES2391914T3 ES 2391914 T3 ES2391914 T3 ES 2391914T3 ES 08709428 T ES08709428 T ES 08709428T ES 08709428 T ES08709428 T ES 08709428T ES 2391914 T3 ES2391914 T3 ES 2391914T3
- Authority
- ES
- Spain
- Prior art keywords
- composition according
- diclofenac
- glycol ether
- ester
- nsaid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000699 topical effect Effects 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 23
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 23
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 16
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960000991 ketoprofen Drugs 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 5
- 239000000194 fatty acid Substances 0.000 claims abstract description 5
- 229930195729 fatty acid Natural products 0.000 claims abstract description 5
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960004752 ketorolac Drugs 0.000 claims abstract description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims abstract 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 52
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 34
- 239000012071 phase Substances 0.000 claims description 23
- 229960001259 diclofenac Drugs 0.000 claims description 22
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 150000002576 ketones Chemical class 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 230000002821 anti-nucleating effect Effects 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 229940044949 eucalyptus oil Drugs 0.000 claims description 3
- 239000010642 eucalyptus oil Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000002667 nucleating agent Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 14
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 230000035515 penetration Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 239000006184 cosolvent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical group CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010587 phase diagram Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- 230000001839 systemic circulation Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960005466 diclofenac diethylammonium Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002085 enols Chemical group 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004349 Polyvinylpyrrolidone-vinyl acetate copolymer Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0704846.5A GB0704846D0 (en) | 2007-03-13 | 2007-03-13 | Topical pharmaceutical formulation |
| GB0704846 | 2007-03-13 | ||
| PCT/GB2008/000540 WO2008110741A2 (en) | 2007-03-13 | 2008-02-15 | Topical pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2391914T3 true ES2391914T3 (es) | 2012-12-03 |
Family
ID=37988913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08709428T Active ES2391914T3 (es) | 2007-03-13 | 2008-02-15 | Formulación farmacéutica tópica |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8541470B2 (enExample) |
| EP (2) | EP2131813B1 (enExample) |
| JP (1) | JP2010521442A (enExample) |
| CN (1) | CN101663022A (enExample) |
| AU (1) | AU2008224735B2 (enExample) |
| BR (1) | BRPI0808887A2 (enExample) |
| CA (1) | CA2680074C (enExample) |
| CO (1) | CO6220926A2 (enExample) |
| DK (1) | DK2131813T3 (enExample) |
| ES (1) | ES2391914T3 (enExample) |
| GB (1) | GB0704846D0 (enExample) |
| MX (1) | MX2009009758A (enExample) |
| MY (1) | MY149545A (enExample) |
| NZ (1) | NZ579895A (enExample) |
| PL (1) | PL2131813T3 (enExample) |
| PT (1) | PT2131813E (enExample) |
| RU (1) | RU2468794C2 (enExample) |
| SG (1) | SG179480A1 (enExample) |
| TW (1) | TWI367110B (enExample) |
| UA (1) | UA100509C2 (enExample) |
| WO (1) | WO2008110741A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1687019T (pt) * | 2003-11-20 | 2018-02-26 | Novo Nordisk As | Formulações de péptidos que contêm polietileno glicol que são ótimas para produção e para utilização em dispositivos de injeção |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| CN102753556B (zh) | 2009-10-14 | 2015-05-13 | 泽农医药公司 | 螺-羟吲哚化合物的合成方法 |
| NZ601667A (en) | 2010-02-26 | 2014-10-31 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US9744132B2 (en) | 2010-10-29 | 2017-08-29 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US11730709B2 (en) | 2010-10-29 | 2023-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US9271950B2 (en) | 2010-10-29 | 2016-03-01 | Infirst Healthcare Limited | Compositions for treating chronic inflammation and inflammatory diseases |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| US9504664B2 (en) | 2010-10-29 | 2016-11-29 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US11202831B2 (en) | 2010-10-29 | 2021-12-21 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| US11224659B2 (en) | 2010-10-29 | 2022-01-18 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US10695432B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in severe pain |
| US9737500B2 (en) | 2010-10-29 | 2017-08-22 | Infirst Healthcare Limited | Compositions and methods for treating severe pain |
| HK1205114A1 (en) | 2012-04-12 | 2015-12-11 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| CN105007947B (zh) * | 2013-01-14 | 2019-02-15 | 因佛斯特医疗有限公司 | 固溶体组合物及其在心血管疾病中的用途 |
| RU2677346C2 (ru) * | 2013-01-14 | 2019-01-16 | ИнФерст Хэлткэр Лимитед | Композиции и способы для лечения сильной боли |
| KR20150129664A (ko) * | 2013-02-04 | 2015-11-20 | 인퍼스트 헬스케어 리미티드 | 만성 염증 및 염증성 질병을 치료하기 위한 조성물 및 방법 |
| US9012402B1 (en) * | 2014-06-11 | 2015-04-21 | James Blanchard | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation |
| US10596117B1 (en) | 2014-12-31 | 2020-03-24 | Eric Morrison | Lipoleosomes as carriers for aromatic amide anesthetic compounds |
| US11007161B1 (en) | 2014-12-31 | 2021-05-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films |
| US10561627B2 (en) | 2014-12-31 | 2020-02-18 | Eric Morrison | Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| GB201502845D0 (en) * | 2015-02-20 | 2015-04-08 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| FR3041534B1 (fr) * | 2015-09-30 | 2019-03-15 | Vetoquinol Sa | Composition de nettoyant auriculaire |
| GB201609968D0 (en) * | 2016-06-07 | 2016-07-20 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
| US20210137829A1 (en) * | 2017-03-07 | 2021-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Topical delivery systems for active compounds |
| US10821075B1 (en) | 2017-07-12 | 2020-11-03 | James Blanchard | Compositions for topical application of a medicaments onto a mammalian body surface |
| HUE066356T2 (hu) | 2017-08-24 | 2024-07-28 | Novo Nordisk As | GLP-1 készítmények és alkalmazásaik |
| PE20221575A1 (es) | 2020-02-18 | 2022-10-06 | Novo Nordisk As | Formulaciones farmaceuticas |
| GB2596286B (en) | 2020-06-20 | 2023-01-25 | Francis Davis Adrian | Adherence to topical therapy |
| WO2022023348A1 (en) | 2020-07-27 | 2022-02-03 | Incanthera (R&D) Ltd | Topical formulation |
| GB2597526A (en) | 2020-07-27 | 2022-02-02 | Incanthera R&D Ltd | Topical formulation |
| GB202012836D0 (en) | 2020-08-17 | 2020-09-30 | Futura Medical Developments Ltd | Topical composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06104624B2 (ja) * | 1986-05-07 | 1994-12-21 | 太郎 小木曽 | 経皮吸収剤 |
| PE20011092A1 (es) | 2000-02-14 | 2001-11-12 | Procter & Gamble | Composiciones para el suministro topico de un agente farmaceuticamente activo que tiene reducida irritacion de la piel |
| DE10019171A1 (de) * | 2000-04-07 | 2001-10-18 | Schering Ag | Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe |
| AR041021A1 (es) * | 2002-08-22 | 2005-04-27 | Novartis Consumer Health Sa | Composicion topica |
| US7132452B2 (en) * | 2003-03-10 | 2006-11-07 | Fang-Yu Lee | Topical formulation having effects on alleviating pain/inflammation caused by herpes virus infection |
| WO2005027977A2 (en) * | 2003-09-22 | 2005-03-31 | Agis Industries (1983) Ltd. | Diclofenac compositions for the treatment of skin disorders |
| EP1588697A1 (en) | 2004-04-16 | 2005-10-26 | Kurt H. Prof. Dr. Bauer | Emulsion gel for topical application of pharmaceuticals |
| US20050244522A1 (en) * | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
-
2007
- 2007-03-13 GB GBGB0704846.5A patent/GB0704846D0/en not_active Ceased
-
2008
- 2008-02-15 CN CN200880007936A patent/CN101663022A/zh active Pending
- 2008-02-15 ES ES08709428T patent/ES2391914T3/es active Active
- 2008-02-15 PT PT08709428T patent/PT2131813E/pt unknown
- 2008-02-15 WO PCT/GB2008/000540 patent/WO2008110741A2/en not_active Ceased
- 2008-02-15 UA UAA200910111A patent/UA100509C2/ru unknown
- 2008-02-15 NZ NZ579895A patent/NZ579895A/en not_active IP Right Cessation
- 2008-02-15 US US12/530,960 patent/US8541470B2/en active Active
- 2008-02-15 RU RU2009136228/15A patent/RU2468794C2/ru active
- 2008-02-15 PL PL08709428T patent/PL2131813T3/pl unknown
- 2008-02-15 JP JP2009553196A patent/JP2010521442A/ja active Pending
- 2008-02-15 BR BRPI0808887-0A patent/BRPI0808887A2/pt not_active Application Discontinuation
- 2008-02-15 DK DK08709428.0T patent/DK2131813T3/da active
- 2008-02-15 EP EP08709428A patent/EP2131813B1/en not_active Not-in-force
- 2008-02-15 AU AU2008224735A patent/AU2008224735B2/en not_active Ceased
- 2008-02-15 EP EP12154983A patent/EP2452671A2/en not_active Withdrawn
- 2008-02-15 MX MX2009009758A patent/MX2009009758A/es active IP Right Grant
- 2008-02-15 MY MYPI20093774A patent/MY149545A/en unknown
- 2008-02-15 CA CA2680074A patent/CA2680074C/en active Active
- 2008-02-15 SG SG2012017497A patent/SG179480A1/en unknown
- 2008-02-20 TW TW097105840A patent/TWI367110B/zh not_active IP Right Cessation
-
2009
- 2009-10-08 CO CO09111579A patent/CO6220926A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2680074C (en) | 2016-07-12 |
| UA100509C2 (ru) | 2013-01-10 |
| CA2680074A1 (en) | 2008-09-18 |
| PL2131813T3 (pl) | 2012-11-30 |
| TW200836769A (en) | 2008-09-16 |
| MX2009009758A (es) | 2009-09-24 |
| TWI367110B (en) | 2012-07-01 |
| EP2131813B1 (en) | 2012-08-08 |
| PT2131813E (pt) | 2012-10-31 |
| GB0704846D0 (en) | 2007-04-18 |
| CO6220926A2 (es) | 2010-11-19 |
| SG179480A1 (en) | 2012-04-27 |
| EP2452671A2 (en) | 2012-05-16 |
| US20100099767A1 (en) | 2010-04-22 |
| JP2010521442A (ja) | 2010-06-24 |
| AU2008224735B2 (en) | 2013-04-18 |
| WO2008110741A2 (en) | 2008-09-18 |
| NZ579895A (en) | 2012-02-24 |
| US8541470B2 (en) | 2013-09-24 |
| WO2008110741A8 (en) | 2009-11-19 |
| RU2009136228A (ru) | 2011-04-20 |
| CN101663022A (zh) | 2010-03-03 |
| WO2008110741A3 (en) | 2009-03-12 |
| RU2468794C2 (ru) | 2012-12-10 |
| BRPI0808887A2 (pt) | 2014-09-02 |
| EP2131813A2 (en) | 2009-12-16 |
| DK2131813T3 (da) | 2012-10-29 |
| AU2008224735A1 (en) | 2008-09-18 |
| MY149545A (en) | 2013-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008224735B2 (en) | Topical pharmaceutical formulation | |
| ES2263182T3 (es) | Composicion adecuada para el tratamiento de laminitis equina. | |
| ES2607476T3 (es) | Composición tópica que contiene ibuprofeno | |
| ES2352222T3 (es) | Preparación farmacéutica y/o cosmética que contiene un organoxilosano y un fosfolípido. | |
| ES2429443T3 (es) | Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada | |
| ES2223277B1 (es) | Composicion anestesica para administracion topica. | |
| ES2445443T3 (es) | Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma | |
| ES2299077T3 (es) | Composición en forma de spray que contiene la asociación de calcitriol y de propionato de clobetasol, una fase alcoholica, al menos una silicona volátil y una fase oleosa no volátil. | |
| ES2599973T3 (es) | Una formulación tópica de propionato de clobetasol de nivel bajo para tratar trastornos de la membrana mucosa y de la piel | |
| ES2985068T3 (es) | Composición tópica que comprende tacrolimus | |
| ES2861374T3 (es) | Composiciones tópicas que comprenden un corticosteroide | |
| CN106572970B (zh) | 用于局部给药非甾体抗炎药以缓解肌肉骨骼疼痛的新型凝胶及其制备方法 | |
| ES2590258T3 (es) | Preparación antiinflamatoria y analgésica para uso externo | |
| US20140275265A1 (en) | Therapeutic cream for application to skin | |
| US20180036269A1 (en) | Topical Pharmaceutical Formulation | |
| ES2220787T3 (es) | Composiciones antifungicas a base de cetoconazol, destinadas a un uso topico. | |
| ES2296209T5 (es) | Composición en forma de un spray que comprende una combinación de propionato de clobetasol y calcitriol, una fase alcohólica y una fase oleosa. | |
| ES2724173T3 (es) | Composición farmacéutica | |
| JP2024507011A (ja) | エマルション組成物、ならびに放射線によって引き起こされる皮膚損傷の予防および／または処置におけるその使用 | |
| ES2328380T3 (es) | Composicion para favorecer la relajacion vascular de los musculos lisos. | |
| CA2500907A1 (en) | Vehicle for topical delivery of anti-inflammatory compounds | |
| ES2758198T3 (es) | Composiciones analgésicas pulverizables | |
| ES2441917B1 (es) | Composición farmacéutica para uso en inflamación y dolor | |
| ES2289897B1 (es) | Composicion para administracion transdermica de agentes fisiologicamente activos. | |
| ES2334857T3 (es) | Preparaciones cosmeticas o dermatologicas contemiendoester metilico de2-isopropilo-5-metilo-ciclohexancarbonilo-d-alanina y una o varios principios activos antiinflamatorios. |